MorphoSys Stock Xetra

Stocks

MOR

DE0006632003

OTC Markets Traded
Market Closed - Xetra 18:36:08 02/08/2024 +03 5-day change 1st Jan Change
67.25 EUR -0.66% Intraday chart for MorphoSys -.--% -
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
3 years 14.52
Extreme 14.52
69.75
5 years 11.8
Extreme 11.805
69.75
10 years 11.8
Extreme 11.805
146.3
Logo MorphoSys
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Employees
446
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!